Systematic literature review of the global burden of illness of mantle cell lymphoma

Curr Med Res Opin. 2020 May;36(5):843-852. doi: 10.1080/03007995.2020.1742101. Epub 2020 Mar 31.

Abstract

Background: Mantle cell lymphoma (MCL), a rare and aggressive disease, accounts for approximately 5% of all B-cell non-Hodgkin's lymphomas. Evidence on the burden of this disease, for patients and healthcare providers, is scarce.Methods: Four systematic literature reviews were developed to identify epidemiological, real-world clinical, economic and humanistic burden data on patients with MCL. Electronic databases searched included MEDLINE and Embase, NHS EED and Econlit.Results: Eight epidemiological studies, 19 clinical burden, 2 economic impact and 0 quality of life studies were identified. The range of standardized MCL incidence rates was 0.1-1.27/100,000. Overall survival rates of patients at 3 years differed by age at diagnosis (≤65 years: 76-81%, >65 years: 46-64%) and disease stage (stage I: 73-80%, stage IV: 48-53%). Outcomes were poorer in previously treated patients, and those with later stage or blastoid disease, and improved with more recent diagnosis/treatment. Hospitalization is a major contributor to healthcare cost and differs by therapy toxicity.Conclusions: We identified significant data gaps for many G20 countries for epidemiology, real-world clinical, economic and humanistic burden. These literature reviews demonstrate the ongoing unmet need for MCL patients globally. Future research to further understand the real-world impact of MCL is needed along with new therapeutic options to improve patient outcomes.

Keywords: Epidemiology; economic burden; lymphoproliferative disorder; rituximab; survival.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adult
  • Aged
  • Cost of Illness*
  • Female
  • Health Care Costs
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy
  • Lymphoma, Mantle-Cell / economics
  • Lymphoma, Mantle-Cell / epidemiology*
  • Lymphoma, Mantle-Cell / mortality
  • Male
  • Middle Aged